Researcher

Robert Horvitz

Profile

Robert Horvitz is an American biologist and Howard Hughes Medical Institute Investigator at MIT who shared the 2002 Nobel Prize in Physiology or Medicine with Sydney Brenner and John Sulston for the genetic regulation of organ development and programmed cell death. Horvitz identified the key genes that control apoptosis in C. elegans, including ced-3 and ced-4 (whose mammalian counterparts are caspases and Apaf-1, respectively) and the death-inhibiting gene ced-9 (counterpart to BCL-2). His discovery that ced-9 is a functional homolog of human BCL-2 was a watershed moment connecting C. elegans genetics to human cancer, because BCL-2 overexpression is a hallmark of follicular lymphoma. The BCL-2 inhibitor venetoclax, approved for leukemia and lymphoma, is a direct clinical descendant of this foundational biology. Horvitz continues to study apoptosis, necrosis, and other cell death pathways in model organisms. Pharmaceutical companies developing cancer therapeutics targeting the apoptotic pathway—including BCL-2 family inhibitors and IAP antagonists—rely on the mechanistic framework established by Horvitz and colleagues.

Industry Ties